Home » Stocks » PBLA

Panbela Therapeutics, Inc. (PBLA)

Stock Price: $4.13 USD 0.07 (1.72%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $4.08 -0.05 (-1.21%) May 7, 6:30 PM
Market Cap 41.67M
Revenue (ttm) n/a
Net Income (ttm) -4.77M
Shares Out 7.73M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $4.13
Previous Close $4.06
Change ($) 0.07
Change (%) 1.72%
Day's Open 4.05
Day's Range 4.05 - 4.20
Day's Volume 6,765
52-Week Range 2.37 - 8.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MINNEAPOLIS, April 06, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...

1 month ago - GlobeNewsWire

MINNEAPOLIS, March 26, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), is re-issuing this press release solely to correct an inadvertent decimal error in the net loss per share repor...

1 month ago - GlobeNewsWire

MINNEAPOLIS, March 25, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...

1 month ago - GlobeNewsWire

MINNEAPOLIS, March 17, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...

1 month ago - GlobeNewsWire

MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wi...

1 month ago - GlobeNewsWire

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Panbela Therapeutics Inc. ("Panbela" or the "Company") (NASDAQ: PBLA). Such investors are advised ...

2 months ago - PRNewsWire

Independent data safety monitoring board (DSMB) has recommended a hold on Panbela Therapeutics Inc's (NASDAQ: PBLA) ongoing Phase 1 trial to hold the administration of SBP-101 pending further investigat...

2 months ago - Benzinga

MINNEAPOLIS, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with...

2 months ago - GlobeNewsWire

MINNEAPOLIS, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer...

Other stocks mentioned: SNBP
5 months ago - GlobeNewsWire

About PBLA

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Thera... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Michael Cullen
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
PBLA
Full Company Profile

Financial Performance

Financial Statements